2025 Q4 -tulosraportti
Äänite tulossa
Tänään
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 | - | - | ||
| 5 339 | - | - | ||
| 3 000 | - | - | ||
| 2 623 | - | - | ||
| 7 377 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·36 min sittenhttps://www.finansavisen.no/finans/2026/04/15/8344174/s-and-p-500-til-ny-rekord-investorene-vedder-pa-iran-fred The fact that the stock market across the pond is going up, with technology stocks in the lead, is also positive for Oslo børs' technology stocks. We see a trend that the «common crowd» is moving from oil stocks and into other segments, e.g. technology.
·2 t sitten · MuokattuHere is a complete overview of the important dates in 2026. Not least the crucial Proof of Concept for CAR-T. It all appears in the annual report. https://drive.google.com/file/d/1Ja_IyIFh3GuqZmC2ximruX1tozRAiWCa/view?usp=sharing
·2 t sittenYes, there it is. A fresh PhD from Karolinska confirms the Circio case. This has gone under the radar, but today Jennifer Geara's doctoral thesis at Karolinska Institutet was published: "Modulating fibroblasts in hard-to-heal wounds and skin ageing: roles of circRNAs". By using terms like "superior stability" (superior stability) and "prolonged therapeutic effect" (long-lasting therapeutic effect), Geara argues that circular RNA solves the biggest problems that have held back conventional RNA therapy. For those who want to read the technical details on how circRNA (e.g., CircMT-RNR2) controls fibroblasts, the entire thesis is available here: https://openarchive.ki.se/articles/thesis/Modulating_fibroblasts_in_hard-to-heal_wounds_and_skin_ageing_roles_of_circRNAs_and_dermal_injectables/31026202?file=63750444 One of the most exciting aspects was that Geara shows we can now identify circRNA sequences that are highly specific for certain cell types or disease states. So instead of administering a medicine that affects the entire body, circRNA technology (like the one Circio is developing) can be used to send a "coded message" that is only read and executed by the fibroblasts that are actually diseased. Overall, this absolutely confirms the case. Good luck, everyone!
·3 min sittenGreat work. This probably has no direct impact on Circio before the company actually manages to confirm a finished product that big Pharmaceuticals or the market can use, or am I wrong?
·2 t sittenFrom the updated owner list, we can see that the major owners who lent out their shares for the emission have finally gotten them back. Two large items on the sell side: 1. THE BANK OF NEW YORK MELLON SA/NV -738 866 (Probably a bank for several major players, still over 2.4 million shares here) 2. NORDNET LIVSFORSIKRING AS -513 625 (IKZ accounts) Good luck tomorrow, hoping things calm down soon 😬
·3 t sittenAi summarizes the most important price drivers as follows:·1 t sittenIt seems to have disappeared. Trying again here: 1. Top‑5 pharma‑partnerships (could become a billion-dollar deal) 2. 50‑fold improvement in AAV (game‑changer) 3. 6 mth CAR‑expression (no one else has this) 4. Runway until 2030 (removes equity issuance risk) 5. Several new partnerships in 2026 6. Densely packed pipeline with many triggers 7. No direct competitors This is an extremely strong combination for a Norwegian biotech company.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Äänite tulossa
Tänään
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·36 min sittenhttps://www.finansavisen.no/finans/2026/04/15/8344174/s-and-p-500-til-ny-rekord-investorene-vedder-pa-iran-fred The fact that the stock market across the pond is going up, with technology stocks in the lead, is also positive for Oslo børs' technology stocks. We see a trend that the «common crowd» is moving from oil stocks and into other segments, e.g. technology.
- ·2 t sitten · MuokattuHere is a complete overview of the important dates in 2026. Not least the crucial Proof of Concept for CAR-T. It all appears in the annual report. https://drive.google.com/file/d/1Ja_IyIFh3GuqZmC2ximruX1tozRAiWCa/view?usp=sharing
- ·2 t sittenYes, there it is. A fresh PhD from Karolinska confirms the Circio case. This has gone under the radar, but today Jennifer Geara's doctoral thesis at Karolinska Institutet was published: "Modulating fibroblasts in hard-to-heal wounds and skin ageing: roles of circRNAs". By using terms like "superior stability" (superior stability) and "prolonged therapeutic effect" (long-lasting therapeutic effect), Geara argues that circular RNA solves the biggest problems that have held back conventional RNA therapy. For those who want to read the technical details on how circRNA (e.g., CircMT-RNR2) controls fibroblasts, the entire thesis is available here: https://openarchive.ki.se/articles/thesis/Modulating_fibroblasts_in_hard-to-heal_wounds_and_skin_ageing_roles_of_circRNAs_and_dermal_injectables/31026202?file=63750444 One of the most exciting aspects was that Geara shows we can now identify circRNA sequences that are highly specific for certain cell types or disease states. So instead of administering a medicine that affects the entire body, circRNA technology (like the one Circio is developing) can be used to send a "coded message" that is only read and executed by the fibroblasts that are actually diseased. Overall, this absolutely confirms the case. Good luck, everyone!·3 min sittenGreat work. This probably has no direct impact on Circio before the company actually manages to confirm a finished product that big Pharmaceuticals or the market can use, or am I wrong?
- ·2 t sittenFrom the updated owner list, we can see that the major owners who lent out their shares for the emission have finally gotten them back. Two large items on the sell side: 1. THE BANK OF NEW YORK MELLON SA/NV -738 866 (Probably a bank for several major players, still over 2.4 million shares here) 2. NORDNET LIVSFORSIKRING AS -513 625 (IKZ accounts) Good luck tomorrow, hoping things calm down soon 😬
- ·3 t sittenAi summarizes the most important price drivers as follows:·1 t sittenIt seems to have disappeared. Trying again here: 1. Top‑5 pharma‑partnerships (could become a billion-dollar deal) 2. 50‑fold improvement in AAV (game‑changer) 3. 6 mth CAR‑expression (no one else has this) 4. Runway until 2030 (removes equity issuance risk) 5. Several new partnerships in 2026 6. Densely packed pipeline with many triggers 7. No direct competitors This is an extremely strong combination for a Norwegian biotech company.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 | - | - | ||
| 5 339 | - | - | ||
| 3 000 | - | - | ||
| 2 623 | - | - | ||
| 7 377 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Äänite tulossa
Tänään
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·36 min sittenhttps://www.finansavisen.no/finans/2026/04/15/8344174/s-and-p-500-til-ny-rekord-investorene-vedder-pa-iran-fred The fact that the stock market across the pond is going up, with technology stocks in the lead, is also positive for Oslo børs' technology stocks. We see a trend that the «common crowd» is moving from oil stocks and into other segments, e.g. technology.
- ·2 t sitten · MuokattuHere is a complete overview of the important dates in 2026. Not least the crucial Proof of Concept for CAR-T. It all appears in the annual report. https://drive.google.com/file/d/1Ja_IyIFh3GuqZmC2ximruX1tozRAiWCa/view?usp=sharing
- ·2 t sittenYes, there it is. A fresh PhD from Karolinska confirms the Circio case. This has gone under the radar, but today Jennifer Geara's doctoral thesis at Karolinska Institutet was published: "Modulating fibroblasts in hard-to-heal wounds and skin ageing: roles of circRNAs". By using terms like "superior stability" (superior stability) and "prolonged therapeutic effect" (long-lasting therapeutic effect), Geara argues that circular RNA solves the biggest problems that have held back conventional RNA therapy. For those who want to read the technical details on how circRNA (e.g., CircMT-RNR2) controls fibroblasts, the entire thesis is available here: https://openarchive.ki.se/articles/thesis/Modulating_fibroblasts_in_hard-to-heal_wounds_and_skin_ageing_roles_of_circRNAs_and_dermal_injectables/31026202?file=63750444 One of the most exciting aspects was that Geara shows we can now identify circRNA sequences that are highly specific for certain cell types or disease states. So instead of administering a medicine that affects the entire body, circRNA technology (like the one Circio is developing) can be used to send a "coded message" that is only read and executed by the fibroblasts that are actually diseased. Overall, this absolutely confirms the case. Good luck, everyone!·3 min sittenGreat work. This probably has no direct impact on Circio before the company actually manages to confirm a finished product that big Pharmaceuticals or the market can use, or am I wrong?
- ·2 t sittenFrom the updated owner list, we can see that the major owners who lent out their shares for the emission have finally gotten them back. Two large items on the sell side: 1. THE BANK OF NEW YORK MELLON SA/NV -738 866 (Probably a bank for several major players, still over 2.4 million shares here) 2. NORDNET LIVSFORSIKRING AS -513 625 (IKZ accounts) Good luck tomorrow, hoping things calm down soon 😬
- ·3 t sittenAi summarizes the most important price drivers as follows:·1 t sittenIt seems to have disappeared. Trying again here: 1. Top‑5 pharma‑partnerships (could become a billion-dollar deal) 2. 50‑fold improvement in AAV (game‑changer) 3. 6 mth CAR‑expression (no one else has this) 4. Runway until 2030 (removes equity issuance risk) 5. Several new partnerships in 2026 6. Densely packed pipeline with many triggers 7. No direct competitors This is an extremely strong combination for a Norwegian biotech company.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 | - | - | ||
| 5 339 | - | - | ||
| 3 000 | - | - | ||
| 2 623 | - | - | ||
| 7 377 | - | - |
Välittäjätilasto
Dataa ei löytynyt